Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Coherus Oncology, Inc.NASDAQ: CHRS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $881K fell 15.8% year over year, behind the +2.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 57.3% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.
Context
- Depreciation & amortization amounted to 9.3% of revenue in FY2025, up 7.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -15.8% toward the trailing-twelve-month pace of +2.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.92M USD
- Year-over-year change
- -25.6%
- 4-year CAGR
- +3.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.92M | -25.6% |
| FY2024 | 2024-12-31 | 5.28M | +39.2% |
| FY2023 | 2023-12-31 | 3.79M | +2.5% |
| FY2022 | 2022-12-31 | 3.7M | +7.1% |
| FY2021 | 2021-12-31 | 3.45M | — |
Depreciation & Amortization vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 depreciation & amortization of $4.93M is the 4th largest of the 11 companies compared; the peer median is $2.11M.
- Its year-over-year change of +2.3% is the 5th highest of 11, against a peer median of -7.6%.
- Depreciation & amortization amounts to 10.5% of revenue for CHRS, versus a peer median of 14.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.65M | +1.1% | +6.0% | 81.8% | |
| LTM Mar 2026 | $6.75M | +171.1% | -20.0% | 8.6% | |
| LTM Mar 2026 | $6.56M | -25.2% | -28.2% | 19.0% | |
| LTM Mar 2026 | $4.93M | +2.3% | +2.0% | 10.5% | |
| LTM Mar 2026 | $3.38M | +84.9% | +5.3% | 9.7% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M | +35.9% | -25.1% | 119.9% |
| LTM Mar 2026 | $1.88M | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $369K | +11.1% | +13.4% | — | |
| LTM Mar 2026 | $226K | -16.3% | +27.5% | 383.1% | |
| LTM Sep 2026 | $152K | -97.9% | — | — | |
| LTM Mar 2026 | $58K | -95.6% | +10.5% | 0.1% | |
| Peer median (excluding CHRS) | $2.11M | -7.6% | +6.0% | 14.3% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | 168.02M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| Deferred Income Tax | 9.44M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 51.36M | 50.74M | 43.11M | 27.8M | 16.97M |
| Change in Working Capital | 42.36M | (79.26M) | (36.83M) | 55.89M | (5.84M) |
| Accounts Receivables | 34.06M | 13.05M | (150.68M) | 149.35M | 93.56M |
| Inventory | (6.25M) | (47.35M) | (46.73M) | (31.95M) | (17.11M) |
| Accounts Payables | 874K | (4.55M) | 23.76M | (3.94M) | (19.56M) |
| Other Working Capital | 13.68M | (40.41M) | 136.83M | (57.57M) | (62.74M) |
| Other Non-Cash Items | 143.05M | 75.45M | 52.93M | (137.92M) | (321.59M) |
| Operating Cash Flow | (37.43M) | (241.12M) | (174.88M) | (20.44M) | (138.51M) |
| Capital Expenditures | (1.29M) | (2.04M) | (286K) | 0 | 0 |
| Acquisitions (Net) | 1.29M | 0 | 845K | 0 | 0 |
| Purchases of Investments | (182.49M) | (127.38M) | (19.51M) | 0 | (103.84M) |
| Sales of Investments | 181.36M | 0 | 157.64M | 14.89M | 21.46M |
| Other Investing Activities | (137.29M) | (37.43M) | 5.95M | 215.43M | 457.46M |
| Investing Cash Flow | (138.41M) | (166.85M) | 144.64M | 230.32M | 375.09M |
| Debt Repayment | (672K) | 49.93M | 0 | (223.41M) | (233.19M) |
| Common Stock Issued | 40.9M | 6.36M | 74.22M | 1.46M | 8.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 54.3M | (1.96M) | (4.62M) | 34.98M | (48.77M) |
| Financing Cash Flow | 51.88M | 54.33M | 69.6M | (186.97M) | (273.71M) |
| Effect of Forex Changes | 0 | 0 | (12K) | 0 | 0 |
| Net Change in Cash | (123.96M) | (353.65M) | 39.34M | 22.91M | (37.13M) |
| Free Cash Flow | (38.72M) | (243.16M) | (175.17M) | (20.44M) | (138.51M) |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.